Ibrahim Turkoz, PhD

Janssen Research & Development, LLC, Titusville, New Jersey

JCP
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
Original Research

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
Oliver J. Lopena, Larry D. Alphs, Martha Sajatovic, et al
JCP
Original Research

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...
Ibrahim Turkoz, Ella Daly, Jaskaran Singh, et al
JCP
Original Research

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.
Peter J. Weiden, Edward Kim, Jason Bermak, et al
JCP
Original Research

December 5, 2014

Dong-Jing Fu, Ibrahim Turkoz, R. Bruce Simonson, et al
JCP
Letter to the Editor

October 15, 2012

Larry Alphs, William H. Olson, Ibrahim Turkoz, et al
JCP
Original Research

May 15, 2010

Carla M. Canuso, Jean-Pierre Lindenmayer, Colette Kosik-Gonzalez, et al
JCP
Original Research

August 15, 2006

George M. Simpson, Ramy A. Mahmoud, Robert A. Lasser, et al
JCP
Letter to the Editor

January 16, 2006

Georges M. Gharabawi, Cynthia A. Bossie, Ramy Mahmoud, et al
JCP
Original Research

February 15, 2005

Jaspreet S. Brar, Rohan Ganguli, Gahan Pandina, et al
JCP
Original Research

March 1, 2004

Glenn W. Currier, James C-Y Chou, David Feifel, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe